Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study

Rhea-AI Summary

Orocidin A/S, a subsidiary of Nordicus Partners (OTCQB: NORD), has successfully completed its first toxicity study for QR-01, a novel treatment for aggressive periodontitis. The study involved dosing hamsters over a 2-week period with concentrations 5-8 times higher than planned for the upcoming pilot efficacy study in patients.

The results demonstrated high drug tolerance in all test subjects, with no adverse reactions or irritation at the buccal application site. Notably, necroscopic cross examination revealed no tissue changes. This successful completion marks a significant milestone for Orocidin, paving the way for the upcoming pivotal eight-week toxicity study.

Positive

• Successful completion of initial toxicity study for QR-01
• No adverse reactions or safety concerns observed at 5-8x planned dosage
• Clear path forward to eight-week pivotal toxicity study

Negative

• None.

News Market Reaction – NORD

+23.06%

1 alert

+23.06% News Effect

On the day this news was published, NORD gained 23.06%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BEVERLY HILLS, California, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, has successively completed its first toxicity study for QR-01, a novel treatment for aggressive periodontitis.

In the study, Orocidin dosed hamsters over a 2-week period with a concentration 5-8 times higher than the planned dose for the upcoming pilot efficacy study in patients.

“We are pleased to report that all animals exhibited high tolerance to the drug, with no adverse reactions and irritation at the buccal application site. No significant side effects were observed and more importantly, the necroscopic cross examination showed no changes in tissues.” said Allan Wehnert, CEO & Founder of Orocidin.

The successful completion of this study marks an important milestone for Orocidin, providing the foundation for the upcoming pivotal eight-week toxicity study.

For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
hr@nordicuspartners.com
Tel +1 310 666 0750

Investor Relations
Jonathan Paterson
Harbor Access Investor Relations
Jonathan.Paterson@Harbor-Access.com
Tel +1 475 477 9401

About Orocidin
Orocidin’s mission is to develop the preferred treatment against aggressive periodontitis. Our innovative therapeutic agent, QR-01, distinguishes itself through its unique ability to provide treatment of both inflammation and bacterial infection.

About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired 100% of Orocidin A/S, a Danish preclinical-stage biotech company developing next-generation therapies for periodontitis and 100% of Bio-Convert ApS, a Danish preclinical-stage biotech company dedicated to revolutionizing the treatment of oral leukoplakia. For more information about Nordicus, please visit: www.nordicuspartners.com, and follow us on LinkedIn, X, Threads and BlueSky.

Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. 

FAQ

What were the results of Orocidin's QR-01 toxicity study for NORD stock?

The toxicity study showed positive results with high drug tolerance, no adverse reactions, and no tissue changes in test subjects, despite using 5-8 times higher concentrations than planned for human trials.

What is the next step for Orocidin's QR-01 development program (NORD)?

The next step is conducting a pivotal eight-week toxicity study, following the successful completion of the initial two-week toxicity study.

How does the QR-01 toxicity study impact NORD's development timeline?

The successful completion of the initial toxicity study represents a significant milestone, allowing the company to proceed with the planned eight-week toxicity study and subsequent pilot efficacy study in patients.

What safety profile did Orocidin's QR-01 demonstrate in the preclinical study?

QR-01 demonstrated a strong safety profile with high tolerance, no adverse reactions, no irritation at the buccal application site, and no tissue changes in necroscopic examination.